Novo Nordisk Initiates U.S. Job Cuts Amid Global Restructuring
Novo Nordisk has commenced layoffs in the United States, its most critical market, with notifications rolling out over the next fortnight. The Danish pharmaceutical giant, renowned for its weight-loss drug Wegovy, aims to streamline operations globally as it vies for dominance against U.S. competitor Eli Lilly in the obesity treatment sector.
Departments spanning human resources to regulatory affairs face reductions. While the exact U.S. impact remains unconfirmed, the firm targets 9,000 global job cuts. This follows similar workforce trimming in Denmark and coincides with new CEO Mike Doustdar's efforts to stabilize investor confidence after Wegovy's sales deceleration.